UGT1A1 and Glucose intolerance: The UGT1A1-RNAi lowered plasma urobilin levels, adiposity, glucose intolerance, hepatic lipid accumulation, and pro-inflammatory kinase signaling pathways, which suggests targeting UGT1A1 to control urobilin levels as a potential therapeutic [52,53].